Du är här

2016-01-22

BB BIOTECH AG : Fourth quarter returns positive, albeit volatile year in biotech investing

BB BIOTECH AG / BB BIOTECH AG : Fourth quarter returns positive, albeit
volatile year inbiotech investing . Processed and transmitted by NASDAQ OMX
Corporate Solutions.The issuer is solely responsible for the content of this
announcement.
BB Biotech increases its dividend significantly to CHF 14.50 per share and
proposes
a five-for-one stock split

The total annual return for BB Biotech's shares for 2015 was +28.2% in CHF,
+41.2% in EUR and +27.1% in USD. Careful and effective stock selection by the
management team within the sector yielded a portfolio performance of +19.0%
in CHF, +31.6% in EUR and +18.0% in USD, well ahead of the US and European
equity markets, which closed the year either unchanged or with mid-single
digit gains (in USD). In keeping with the payout policy established in 2013,
the Board of Directors will propose a dividend distribution of CHF 14.50 per
share at the upcoming annual general meeting, representing another
substantial increase year-on-year and corresponding to a yield of 5%. In view
of the positive long-term outlook for BB Biotech's portfolio, the Board of
Directors will propose a five-for-one stock split.

Sector rebound in the fourth quarter

Equity market prices rose in the fourth quarter. Most US and European indices
closed the year either unchanged or with mid-single digit gains (in USD).
Strong fundamentals of the biotechnology industry sector and attractive
valuations of leading biotechnology companies led to another quarter of
outperformance compared to broad equity benchmarks.

During the fourth quarter, the Nasdaq Biotech Index (NBI) gained 11.8% in USD,
ahead of the S&P 500 Index, which gained 7.0%. Overall, the four quarters for
NBI in 2015 reflected a volatile year including, sequentially: Extension of
the 2014 rally into Q1 (+13.3%), stagnation in Q2 (+7.5%), correction in Q3
(-17.9%) and a rebound in Q4 (+11.8%), all values in USD.

Consequently during 2015 the NBI gained 11.8% in USD versus the S&P 500 which
ended the year at +1.4% in USD. European indices such as the Euro Stoxx 600
or the DAX gained around 10% in EUR associated with significant weakening of
the Euro, and the SMI's total return for 2015 was a slim +1.2% in CHF.

BB Biotech performance for the fourth quarter and full year 2015

The share price of BB Biotech gained 12.6% in CHF, 12.5% in EUR, and 9.6% in
USD during the fourth quarter. This contributed positively to BB Biotech's
satisfying 2015 total return of 28.2% in CHF, 41.2% in EUR, and 27.1% in USD.

The Net Asset Value (NAV) of BB Biotech gained 14.7% in CHF, 15.0% in EUR and
11.6% in USD in the fourth quarter. For the full year, the NAV increased by
19.0% in CHF, 31.6% in EUR and 18.0% in USD. This performance was driven by
biotech sector performance, careful and effective stock selection by the
management team and a high level of M&A activity.

Based on preliminary unaudited consolidated results, BB Biotech AG closed the
past year with a profit of CHF 653 million (versus a profit of CHF 1'470
million in the previous year). Following the loss of CHF 575 million in the
third quarter, BB Biotech AG rebounded with a profit of CHF 511 million in
the fourth quarter of 2015. Equity market volatility in the second half year
of 2015 drove highly variable quarterly results.

Proposed distribution of CHF 14.50 per share for the fiscal year 2015

In line with the distribution policy established in 2013, the board will
propose a distribution of CHF 14.50 per share at the Annual General Meeting
(AGM) on March 17, 2016, applying a 5% yield to the volume-weighted average
share price during December 2015. This represents a substantial dividend
increase relative to the previous year. The remaining paid-in capital
reserves of around CHF 136 million will be distributed with the difference to
be paid out as a regular dividend from retained earnings.

Proposed five-for-one stock split

The strong performance of the last five years, resulting in a total return of
+461.4% in CHF, and the positive prospects for BB Biotech's portfolio allow
for the proposed five-for-one stock split. The fully diluted number of
authorized shares will increase from 11.85 million shares to 59.25 million
shares, excluding shares repurchased on the second trading line.

Two portfolio additions in the fourth quarter

A slight increase in fund leverage reflects smaller adjustments to the
portfolio in the fourth quarter. At the end of 2015 BB Biotech's portfolio
consists of six core holdings above 5%, namely Celgene, Incyte, Ionis
Pharmaceuticals (their name recently changed from Isis), Actelion, Gilead and
Radius Health. BB Biotech's investment portfolio comprises 34 positions in
all.

Two new portfolio holdings were added in the last quarter of 2015 - Sage
Therapeutics and Cidara Therapeutics. Sage is focused on central nervous
system (CNS) disorders with its lead pipeline candidate SAGE-547 under
development to treat super-refractory status epilepticus. Cidara is
developing novel anti-infectives, including their lead product CD101, a novel
molecule from the echinocandin class, for the treatment of systemic Candida
infections.

Outlook

Many important pipeline read-outs and potential product approvals are expected
among BB Biotechs portfolio holdings in 2016. Merger and acquisition activity
made an important contribution to gains in 2015, and the team foresees more
of the same ahead. On the other hand BB Biotech believes that the macro
environment, including divergent central bank actions and an election year in
the US, may add volatility in the next quarters. BB Biotech's portfolio
consists of established, attractively valued and profitable companies as well
as innovation-focused smaller/midcap companies. The management team believes
this diversity can capture many of the important value-creating sector
milestones in 2016.

The complete annual report as of December 31, 2015 will be published
onFebruary 19, 2016.

For further information:

Investor Relations

Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, tel.
+41 44 267 67 00
Dr. Silvia Schanz,ssc@bellevue.ch
Maria-Grazia Iten-Alderuccio,mga@bellevue.ch

Claude Mikkelsen,cmi@bellevue.ch

Media Relations

Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, tel.
+41 44 267 67 00
Tanja Chicherio,tch@bellevue.ch

b-public AG, Pfingstweidstrasse 6, 8005 Zürich, Switzerland, tel. +41 79 423
22 28
Thomas Egger,teg@b-public.ch

www.bbbiotech.com

Company profile

BB Biotech invests in companies in the fast growing market of biotechnology
and is one of the world's largest investors in this sector with CHF 4.0 bn in
assets under management. BB Biotech is listed in Switzerland, Germany and
Italy. Its investments are focused on listed companies that are developing
and commercializing novel medical treatments and cures. BB Biotech's
investment selection process is guided by the fundamental research and
analysis of physicians and molecular biologists. Its Board of Directors has
many years of experience in industry and science.

Disclaimer

This release contains forward-looking statements and expectations as well as
assessments, beliefs and assumptions. Such statements are based on the
current expectations of BB Biotech, its directors and officers, and are,
therefore, subject to risks and uncertainties that may change over time. As
actual developments may significantly differ, BB Biotech and its directors
and officers accept no responsibility in that regard. All forward-looking
statements included in this release are made only as of the date of this
release and BB Biotech and its directors and officers assume no obligation to
update any forward-looking statements as a result of new information, future
events or other factors.

Composition of BB Biotech's portfolio as of December 31, 2015

(in % of securities, rounded values)

----------------------------------------------------------------------------
| Celgene 10.5% |
| Incyte 9.9% |
| Ionis Pharmaceuticals 9.8% |
| Actelion 7.5% |
| Gilead 6.8% |
| Radius Health 6.4% |
| |
| Alexion Pharmaceuticals 4.8% |
| Neurocrine Biosciences 4.3% |
| Vertex Pharmaceuticals 4.2% |
| Agios Pharmaceuticals 3.4% |
| Novo Nordisk 3.2% |
| Medivation 3.0% |
| Halozyme Therapeutics 3.0% |
| Regeneron Pharmaceuticals 2.7% |
| Alnylam Pharmaceuticals 2.6% |
| Swedish Orphan Biovitrum 2.1% |
| Novavax 1.7% |
| Tesaro 1.6% |
| Cempra 1.5% |
| Juno Therapeutics 1.4% |
| Alder Biopharmaceuticals 1.2% |
| Kite Pharma 1.1% |
| PTC Therapeutics 1.0% |
| Sage Therapeutics 1.0% |
| Intercept Pharmaceuticals 0.9% |
| Puma Biotechnology 0.8% |
| Probiodrug 0.7% |
| Prothena Corp. 0.5% |
| Infinity Pharmaceuticals 0.5% |
| Esperion Therapeutics 0.5% |
| |
| |
|Clovis Oncology 0.4% |
| Achillion Pharmaceuticals 0.3% |
| Cidara Therapeutics 0.2% |
| Tetraphase Pharmaceuticals 0.1% |
...

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.